Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

closerlook

- PMLiVE

Medscape Education Brings AI to the Hematology Frontline at EHA 2026

Medscape Education is supporting a dedicated AI symposium at the 2026 European Hematology Association (EHA) Annual Congress in Stockholm on June 11, 2026.

Medscape Education

- PMLiVE

Bridging the value gap: The systems, teams and mindsets that matter

In pharma, the challenge is no longer understanding what HCPs want from digital. It’s delivering it consistently. In this webinar, we explored what needs to change inside organisations to make...

Graphite Digital

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

Lilly to acquire Curevo in deal worth $1.5bn

The acquisition will help build Lilly’s infectious disease portfolio

- PMLiVE

Bristol Myers Squibb announces strategic agreement with Anthropic

The collaboration builds on more than three years of AI investment by the company

- PMLiVE

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn

Catalyst Pharmaceuticals is focused on novel medicines for rare diseases

- PMLiVE

Personalization, automation and actionable intelligence: How to achieve purposeful innovation in healthcare communications

By Aaron Fletcher

Amiculum

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

A simplified three-step process for achieving the fundamentals of omnichannel engagement in pharma: how to deliver impactful, connected experiences

By Aaron Fletcher

Amiculum

- PMLiVE

Lilly to acquire Centessa in deal worth up to $7.8bn

The companies aim to advance treatments for narcolepsy and other sleep-wake disorders

- PMLiVE

Biogen to acquire Apellis in $5.6bn deal

The deal will enhance Biogen’s growth portfolio in immunology and rare disease

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links